EW — Edwards Lifesciences Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual cashflow statement for Edwards Lifesciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	823	1,503	1,522	1,399	4,170
Depreciation
Deferred Taxes
Non-Cash Items	131	-9.7	233	150	-3,200
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	42.2	145	-421	-526	-259
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Net Change in Other Assets & Liabilities
Cash from Operating Activities	1,054	1,732	1,218	896	542
Capital Expenditures	-407	-330	-265	-266	-282
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-124	-1,393	517	440	2,595
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-531	-1,723	252	174	2,313
Financing Cash Flow Items	-1.2	-0.3	-3.6	-1	-3.1
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-487	-356	-1,585	-711	-983
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	15.8	-333	-94.8	375	1,911